Your session is about to expire
← Back to Search
Nivolumab + BMS-986205 for Endometrial Cancer
Study Summary
This trial will compare the effects of the immunotherapy drug nivolumab, with or without the experimental drug BMS-986205. The addition of BMS-986205 to nivolumab may improve treatment results, but may also cause side effects.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I experience seizures that my medication cannot control.I have had one platinum-based chemotherapy for endometrial cancer.I am fully active or can carry out light work.You have received an organ transplant from another person in the past.My condition is recurrent or persistent endometrial cancer or carcinosarcoma.I am fully active or can carry out light work.I have had up to three treatments for my recurring cancer.I have had another type of cancer before.I had major surgery less than 4 weeks ago.I have not received a live vaccine in the last 30 days.I can provide previous biopsy samples or am willing to have a new biopsy.I am a woman over 18 with an expected lifespan of at least 12 weeks.I am a woman over 18 with an expected lifespan of 3 months or more.I have had up to 3 chemotherapy treatments for my recurring cancer. Hormone treatments don’t count.I have been treated with specific immune therapy drugs before.I haven't taken cancer drugs in the last 21 days or hormone therapy in the last 7 days.I have fluid buildup in my abdomen that treatments haven't helped.I have had pneumonitis or lung disease treated with steroids.My side effects from recent cancer treatments are mild, except for hair loss or nerve issues.I have had an autoimmune disease in the last 2 years.I have brain metastases that need treatment.I have at least one tumor that can be measured with scans or exams.You have enough infection-fighting white blood cells, called neutrophils, in your body.I have a G6PD deficiency and high methemoglobin levels in my blood.I have had cancer spread to the lining of my brain and spinal cord.I or my family have a history of conditions that could lead to high methemoglobin levels.I do not have any unmanaged ongoing illnesses.You need to have a certain number of platelets in your blood, which is 75 x 10^9/L or more.You have a medical condition that makes it difficult to evaluate the study treatment or interpret the results.My cancer is known to have mismatch repair deficiency.I have a confirmed diagnosis of recurrent or persistent endometrial cancer.I have or had inflammatory bowel disease.My organs and bone marrow are functioning well.I have had one platinum-based chemotherapy for endometrial cancer or carcinosarcoma.I have been diagnosed with tuberculosis in the past.My side effects from recent treatments are mild or gone.I have at least one measurable tumor that can be tracked for treatment response.I am not able to become pregnant or I have a negative pregnancy test.I haven't taken immunosuppressive drugs in the last 28 days, with some exceptions.I had a severe reaction to previous immune therapy.I have a condition that affects how my body absorbs pills.
- Group 1: Nivolumab alone
- Group 2: Nivolumab with IDO-inhibitor, BMS- 986205
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What is the geographic scope of this clinical investigation?
"This clinical trial is offered in 7 distinct locations, such as Memorial Sloan Kettering Basking Ridge in Basking Ridge, Middletown's Memorial Sloan Kettering Monmouth, and the renowned Memorial Sloan Kettering Cancer Center located in New york."
Are there vacant slots to join this experiment?
"According to clinicaltrials.gov, the recruitment period for this medical trial has closed; it was initially announced on September 24th 2019 and last updated November 29th 2022. Although no longer actively recruiting patients, there are still a plethora of other trials searching for participants."
What is the capacity of this research project?
"At this moment, the trial is not recruiting any new patients. The study was first published on September 24th 2019 and last updated on November 29th 2022. However, if you are seeking alternative trials, there are currently 309 clinical studies for endometrial neoplasms and 718 Nivolumab-related experiments that require participants."
Does this medical trial represent a pioneering approach to healthcare?
"Nivolumab is part of 718 active trials across 2354 cities and 49 nations. The initial evaluation was conducted by Ono Pharmaceutical Co. Ltd in 2012, with 659 participants taking part in Phase 1 & 2 testing. After this pioneering research concluded, subsequent 259 studies have been completed up to now."
To what extent is Nivolumab utilized to treat medical conditions?
"Nivolumab is a commonly prescribed drug for treating malignancy. It can also be used to address unresectable melanoma, squamous cell carcinoma, and metastatic esophageal adenocarcinomas."
Has the Nivolumab drug been authorized by the Food and Drug Administration?
"Considering the fact that Nivolumab is still in its Phase 2 clinical trials, where there has only been some evidence of safety but none of efficacy, our team at Power assigned it a score of 2."
What other exploratory studies have been conducted with regard to Nivolumab?
"At present, there are 718 research studies dedicated to Nivolumab's efficacy. Of those experiments, 82 have progressed to Phase 3 and can be found in 40237 sites across the globe with a majority of them located in Basel, BE."
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger